The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d’Azur, Nice, France)
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics, Consent, Informative Procedures, and Confidentiality
2.2. Frozen Tissue Management
2.3. FFPE Tissue SPECIMEN Management
2.4. Blood Sample Management
2.5. Sample Management Workflow and Methodology for Inclusion into the Lymphoma Collection
2.6. Clinico-Epidemiological Data and Patient Follow-Up
2.7. Statistics and Graphics
3. Results
3.1. Biological Resources
3.2. Histological Data
3.3. Clinical Data
4. Discussion
- -
- Quantitative data: The number of patients who signed informed consent for the collection of their biological samples and clinically associated data. The number of FFPE blocks and the number and weight/volume of frozen tissues in cryotubes.
- -
- Qualitative data: Cold ischemia time before the tissue was frozen and processed. Delay between blood sampling, centrifugation, and storage at −80 °C in the laboratory. A block of FFPE tissue, taken as a mirror sample of the frozen sample, was cut and stained to confirm and quantify the tumor content of the corresponding frozen sample. These qualitative data reflected the handling of the pre-analytical phase [29,30,31].
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Campo, E.; Jaffe, E.S.; Cook, J.R.; Quintanilla-Martinez, L.; Swerdlow, S.H.; Anderson, K.C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood 2022, 140, 1229–1253. [Google Scholar] [CrossRef] [PubMed]
- Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Attygalle, A.D.; Araujo, I.B.d.O.; Berti, E.; Bhagat, G.; Borges, A.M.; Boyer, D.; Calaminici, M.; et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef] [PubMed]
- Kamdar, M.; Solomon, S.R.; Arnason, J.; Johnston, P.B.; Glass, B.; Bachanova, V.; Ibrahimi, S.; Mielke, S.; Mutsaers, P.; Hernandez-Ilizaliturri, F.; et al. Lisocabtagene Maraleucel versus Standard of Care with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (TRANSFORM): Results from an Interim Analysis of an Open-Label, Randomised, Phase 3 Trial. Lancet 2022, 399, 2294–2308. [Google Scholar] [CrossRef]
- Budde, L.E.; Assouline, S.; Sehn, L.H.; Schuster, S.J.; Yoon, S.-S.; Yoon, D.H.; Matasar, M.J.; Bosch, F.; Kim, W.S.; Nastoupil, L.J.; et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J. Clin. Oncol. 2022, 40, 481–491. [Google Scholar] [CrossRef]
- Opat, S.; Tedeschi, A.; Linton, K.; McKay, P.; Hu, B.; Chan, H.; Jin, J.; Sobieraj-Teague, M.; Zinzani, P.L.; Coleman, M.; et al. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clin. Cancer Res. 2021, 27, 6323–6332. [Google Scholar] [CrossRef]
- Tilly, H.; Morschhauser, F.; Sehn, L.H.; Friedberg, J.W.; Trněný, M.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; Matasar, M.; Rai, S.; et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 386, 351–363. [Google Scholar] [CrossRef]
- Locke, F.L.; Miklos, D.B.; Jacobson, C.A.; Perales, M.-A.; Kersten, M.-J.; Oluwole, O.O.; Ghobadi, A.; Rapoport, A.P.; McGuirk, J.; Pagel, J.M.; et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 386, 640–654. [Google Scholar] [CrossRef]
- Miranda-Filho, A.; Piñeros, M.; Znaor, A.; Marcos-Gragera, R.; Steliarova-Foucher, E.; Bray, F. Global Patterns and Trends in the Incidence of Non-Hodgkin Lymphoma. Cancer Causes Control 2019, 30, 489–499. [Google Scholar] [CrossRef]
- Iglesias-Lopez, C.; Agustí, A.; Vallano, A.; Obach, M. Current Landscape of Clinical Development and Approval of Advanced Therapies. Mol. Ther. Methods Clin. Dev. 2021, 23, 606–618. [Google Scholar] [CrossRef]
- Wang, L.; Qin, W.; Huo, Y.-J.; Li, X.; Shi, Q.; Rasko, J.E.J.; Janin, A.; Zhao, W.-L. Advances in Targeted Therapy for Malignant Lymphoma. Signal Transduct. Target. Ther. 2020, 5, 15. [Google Scholar] [CrossRef]
- Xie, X.; Li, X.; Song, W. Tumor Organoid Biobank-New Platform for Medical Research. Sci. Rep. 2023, 13, 1819. [Google Scholar] [CrossRef]
- Li, H.; Liu, H.; Chen, K. Living Biobank-Based Cancer Organoids: Prospects and Challenges in Cancer Research. Cancer Biol. Med. 2022, 19, 965–982. [Google Scholar] [CrossRef]
- Hewitt, R. Biobanking: The Foundation of Personalized Medicine. Curr. Opin. Oncol. 2021, 23, 112–119. [Google Scholar] [CrossRef]
- Hawkins, A.K. Biobanks: Importance, Implications and Opportunities for Genetic Counselors. J. Genet. Couns. 2010, 19, 423–429. [Google Scholar] [CrossRef]
- Riegman, P.H.J.; Dinjens, W.N.M.; Oosterhuis, J.W. Biobanking for Interdisciplinary Clinical Research. Pathobiology 2007, 74, 239–244. [Google Scholar] [CrossRef]
- Plebani, M. The Detection and Prevention of Errors in Laboratory Medicine. Ann. Clin. Biochem. 2010, 47, 101–110. [Google Scholar] [CrossRef]
- Freedman, L.P.; Cockburn, I.M.; Simcoe, T.S. The Economics of Reproducibility in Preclinical Research. PLoS Biol. 2015, 13, e1002165. [Google Scholar] [CrossRef]
- Botti, G.; Franco, R.; Cantile, M.; Ciliberto, G.; Ascierto, P.A. Tumor Biobanks in Translational Medicine. J. Transl. Med. 2012, 10, 204. [Google Scholar] [CrossRef]
- Braun, L.; Lesperance, M.; Mes-Massons, A.-M.; Tsao, M.S.; Watson, P.H. Individual Investigator Profiles of Biospecimen Use in Cancer Research. Biopreservation Biobanking 2014, 12, 192–198. [Google Scholar] [CrossRef]
- De Blasio, P.; Biunno, I. New Challenges for Biobanks: Accreditation to the New ISO 20387:2018 Standard Specific for Biobanks. BioTech 2021, 10, 13. [Google Scholar] [CrossRef] [PubMed]
- Hofman, V.; Bonnetaud, C.; Gaziello, M.C.; Ilie, M.; Lassalle, S.; Butori, C.; Lerda, N.; Selva, E.; Gavric-Tanga, V.; Castillo, L.; et al. The Nice CHU biobank experience to collect patients’ informed consent for research context (2004–2009). Ann. Pathol. 2010, 30, 337–343. [Google Scholar] [CrossRef]
- Tanga, V.; Leroy, S.; Fayada, J.; Hamila, M.; Allegra, M.; Messaoudi, Z.; Bonnetaud, C.; Lespinet, V.; Bordone, O.; Washetine, K.; et al. Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France). Biopreservation Biobanking 2020, 18, 517–524. [Google Scholar] [CrossRef] [PubMed]
- Khatir, W.; Humbert, O.; Benzaquen, J.; Bontoux, C.; Neels, J.; Berland, L.; Rivera, F.A.G.; Allegra, M.; Salah, M.; Tanga, V.; et al. Identification of a Circulating Immunological Signature Predictive of Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Clin. Transl. Med. 2022, 12, e1018. [Google Scholar] [CrossRef] [PubMed]
- Laurent, C.; Baron, M.; Amara, N.; Haioun, C.; Dandoit, M.; Maynadié, M.; Parrens, M.; Vergier, B.; Copie-Bergman, C.; Fabiani, B.; et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients from the French Lymphopath Network. J. Clin. Oncol. 2017, 35, 2008–2017. [Google Scholar] [CrossRef]
- Alcazer, V. StatAid: An R Package with a Graphical User Interface for Data Analysis. JOSS 2020, 5, 2630. [Google Scholar] [CrossRef]
- Hofman, V.; Ilie, M.; Long, E.; Washetine, K.; Chabannon, C.; Figarella-Branger, D.; Clément, B.; Mabile, L.; Cambon-Thomsen, A.; Boucher, P.; et al. Measuring the Contribution of Tumor Biobanks to Research in Oncology: Surrogate Indicators and Bibliographic Output. Biopreservation Biobanking 2013, 11, 235–244. [Google Scholar] [CrossRef]
- Yong, W.H.; Dry, S.M.; Shabihkhani, M. A Practical Approach to Clinical and Research Biobanking. Methods Mol. Biol. 2014, 1180, 137–162. [Google Scholar] [CrossRef]
- Ellervik, C.; Vaught, J. Preanalytical Variables Affecting the Integrity of Human Biospecimens in Biobanking. Clin. Chem. 2015, 61, 914–934. [Google Scholar] [CrossRef]
- Hubel, A.; Spindler, R.; Skubitz, A.P.N. Storage of Human Biospecimens: Selection of the Optimal Storage Temperature. Biopreservation Biobanking 2014, 12, 165–175. [Google Scholar] [CrossRef]
- Ma, Y.; Dai, H.; Kong, X. Impact of Warm Ischemia on Gene Expression Analysis in Surgically Removed Biosamples. Anal. Biochem. 2012, 423, 229–235. [Google Scholar] [CrossRef]
- Groelz, D.; Viertler, C.; Pabst, D.; Dettmann, N.; Zatloukal, K. Impact of Storage Conditions on the Quality of Nucleic Acids in Paraffin Embedded Tissues. PLoS ONE 2018, 13, e0203608. [Google Scholar] [CrossRef]
- Guyard, A.; Boyez, A.; Pujals, A.; Robe, C.; Tran Van Nhieu, J.; Allory, Y.; Moroch, J.; Georges, O.; Fournet, J.-C.; Zafrani, E.-S.; et al. DNA Degrades during Storage in Formalin-Fixed and Paraffin-Embedded Tissue Blocks. Virchows Arch. 2017, 471, 491–500. [Google Scholar] [CrossRef]
- Fogli, L.K.; Williams, M.E.; Connors, J.M.; Reid, Y.; Brown, K.; O’Connor, O.A. Development and Characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection. Leuk. Lymphoma 2015, 56, 2114–2122. [Google Scholar] [CrossRef]
- Ghesquières, H.; Rossi, C.; Cherblanc, F.; Le Guyader-Peyrou, S.; Bijou, F.; Sujobert, P.; Fabbro-Peray, P.; Bernier, A.; Belot, A.; Chartier, L.; et al. A French Multicentric Prospective Prognostic Cohort with Epidemiological, Clinical, Biological and Treatment Information to Improve Knowledge on Lymphoma Patients: Study Protocol of the “REal World DAta in LYmphoma and Survival in Adults” (REALYSA) Cohort. BMC Public Health 2021, 21, 432. [Google Scholar] [CrossRef]
- Sibon, D.; Bisig, B.; Bonnet, C.; Bachy, E.; Cavalieri, D.; Fataccioli, V.; Drieux, F.; Bruneau, J.; Lemonnier, F.; Bossard, C.; et al. Impact of Dusp22 Rearrangement on the Prognosis of Systemic Alk-Negative Anaplastic Large Cell Lymphoma: A Lysa and Tenomic Study. Hematol. Oncol. 2021, 39, 1590–1603. [Google Scholar] [CrossRef]
- Faumont, N.; Taoui, O.; Collares, D.; Jais, J.-P.; Leroy, K.; Prévaud, L.; Jardin, F.; Molina, T.J.; Copie-Bergman, C.; Petit, B.; et al. C-Rel Is the Pivotal NF-ΚB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. Front. Oncol. 2021, 11, 638897. [Google Scholar] [CrossRef]
- McCulloch, R.; Smith, A.; Wainman, B.; Ingram, W.; Lewis, A.; Hawkins, M.; Crosbie, N.; Pettitt, A.; Rule, S. 40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study. Blood 2019, 134, 2821. [Google Scholar] [CrossRef]
- Bobée, V.; Ruminy, P.; Marchand, V.; Viailly, P.-J.; Abdel Sater, A.; Veresezan, L.; Drieux, F.; Bérard, C.; Bohers, E.; Mareschal, S.; et al. Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. J. Mol. Diagn. 2017, 19, 892–904. [Google Scholar] [CrossRef]
- Glimelius, B.; Melin, B.; Enblad, G.; Alafuzoff, I.; Beskow, A.; Ahlström, H.; Bill-Axelson, A.; Birgisson, H.; Björ, O.; Edqvist, P.-H.; et al. U-CAN: A Prospective Longitudinal Collection of Biomaterials and Clinical Information from Adult Cancer Patients in Sweden. Acta Oncol. 2018, 57, 187–194. [Google Scholar] [CrossRef]
- Cheng, L.; Shi, C.; Wang, X.; Li, Q.; Wan, Q.; Yan, Z.; Zhang, Y. Chinese Biobanks: Present and Future. Genet. Res. 2013, 95, 157–164. [Google Scholar] [CrossRef] [PubMed]
- Nagai, A.; Hirata, M.; Kamatani, Y.; Muto, K.; Matsuda, K.; Kiyohara, Y.; Ninomiya, T.; Tamakoshi, A.; Yamagata, Z.; Mushiroda, T.; et al. Overview of the BioBank Japan Project: Study Design and Profile. J. Epidemiol. 2017, 27, S2–S8. [Google Scholar] [CrossRef] [PubMed]
- Savage, K.J. Primary Mediastinal Large B-Cell Lymphoma. Blood 2022, 140, 955–970. [Google Scholar] [CrossRef] [PubMed]
- Ansell, S.M. Hodgkin Lymphoma: A 2020 Update on Diagnosis, Risk-Stratification, and Management. Am. J. Hematol. 2020, 95, 978–989. [Google Scholar] [CrossRef] [PubMed]
- Thandra, K.C.; Barsouk, A.; Saginala, K.; Padala, S.A.; Barsouk, A.; Rawla, P. Epidemiology of Non-Hodgkin’s Lymphoma. Med. Sci. 2021, 9, 5. [Google Scholar] [CrossRef]
- Smith, A.; Crouch, S.; Lax, S.; Li, J.; Painter, D.; Howell, D.; Patmore, R.; Jack, A.; Roman, E. Lymphoma Incidence, Survival and Prevalence 2004-2014: Sub-Type Analyses from the UK’s Haematological Malignancy Research Network. Br. J. Cancer 2015, 112, 1575–1584. [Google Scholar] [CrossRef]
- Dores, G.M.; Landgren, O.; McGlynn, K.A.; Curtis, R.E.; Linet, M.S.; Devesa, S.S. Plasmacytoma of Bone, Extramedullary Plasmacytoma, and Multiple Myeloma: Incidence and Survival in the United States, 1992–2004. Br. J. Haematol. 2009, 144, 86–94. [Google Scholar] [CrossRef]
- Cheah, C.Y.; Zucca, E.; Rossi, D.; Habermann, T.M. Marginal Zone Lymphoma: Present Status and Future Perspectives. Haematologica 2022, 107, 35–43. [Google Scholar] [CrossRef]
- Ruppert, A.S.; Dixon, J.G.; Salles, G.; Wall, A.; Cunningham, D.; Poeschel, V.; Haioun, C.; Tilly, H.; Ghesquieres, H.; Ziepert, M.; et al. International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020, 135, 2041–2048. [Google Scholar] [CrossRef]
- Gallamini, A.; Stelitano, C.; Calvi, R.; Bellei, M.; Mattei, D.; Vitolo, U.; Morabito, F.; Martelli, M.; Brusamolino, E.; Iannitto, E.; et al. Peripheral T-Cell Lymphoma Unspecified (PTCL-U): A New Prognostic Model from a Retrospective Multicentric Clinical Study. Blood 2004, 103, 2474–2479. [Google Scholar] [CrossRef]
- Male Gender Is an Independent Predictor for Worse Survival and Relapse in a Large, Consecutive Cohort of Elderly DLBCL Patients Treated with R-CHOP. Available online: https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15927 (accessed on 27 December 2022).
- Bontoux, C.; Simonin, M.; Garnier, N.; Lhermitte, L.; Touzart, A.; Andrieu, G.; Bruneau, J.; Lengliné, E.; Plesa, A.; Boissel, N.; et al. Oncogenetic Landscape of T-Cell Lymphoblastic Lymphomas Compared to T-Cell Acute Lymphoblastic Leukemia. Mod. Pathol. 2022, 35, 1227–1235. [Google Scholar] [CrossRef]
- Simonin, M.; Schmidt, A.; Bontoux, C.; Dourthe, M.-É.; Lengliné, E.; Andrieu, G.P.; Lhermitte, L.; Graux, C.; Grardel, N.; Cayuela, J.-M.; et al. Oncogenetic Landscape and Clinical Impact of IDH1 and IDH2 Mutations in T-ALL. J. Hematol. Oncol. 2021, 14, 74. [Google Scholar] [CrossRef]
- Rodrigues, J.M.; Porwit, A.; Hassan, M.; Ek, S.; Jerkeman, M. Targeted Genomic Investigations in a Population-Based Cohort of Mantle Cell Lymphoma Reveal Novel Clinically Relevant Targets. Leuk. Lymphoma 2021, 62, 2637–2647. [Google Scholar] [CrossRef]
- Zhu, Y.; Weiss, T.; Zhang, Q.; Sun, R.; Wang, B.; Yi, X.; Wu, Z.; Gao, H.; Cai, X.; Ruan, G.; et al. High-Throughput Proteomic Analysis of FFPE Tissue Samples Facilitates Tumor Stratification. Mol. Oncol. 2019, 13, 2305–2328. [Google Scholar] [CrossRef]
- Washetine, K.; Heeke, S.; Bonnetaud, C.; Kara-Borni, M.; Ilié, M.; Lassalle, S.; Butori, C.; Long-Mira, E.; Marquette, C.H.; Cohen, C.; et al. Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How? Cancers 2018, 10, 220. [Google Scholar] [CrossRef]
- Bevilacqua, G.; Bosman, F.; Dassesse, T.; Höfler, H.; Janin, A.; Langer, R.; Larsimont, D.; Morente, M.M.; Riegman, P.; Schirmacher, P.; et al. The Role of the Pathologist in Tissue Banking: European Consensus Expert Group Report. Virchows Arch. 2010, 456, 449–454. [Google Scholar] [CrossRef]
- Hewitt, R.; Hainaut, P. Biobanking in a Fast Moving World: An International Perspective. J. Natl. Cancer Inst. Monogr. 2011, 2011, 50–51. [Google Scholar] [CrossRef]
- Rogers, J.; Carolin, T.; Vaught, J.; Compton, C. Biobankonomics: A Taxonomy for Evaluating the Economic Benefits of Standardized Centralized Human Biobanking for Translational Research. J. Natl. Cancer Inst. Monogr. 2011, 2011, 32–38. [Google Scholar] [CrossRef]
- Vaught, J.; Rogers, J.; Carolin, T.; Compton, C. Biobankonomics: Developing a Sustainable Business Model Approach for the Formation of a Human Tissue Biobank. J. Natl. Cancer Inst. Monogr. 2011, 2011, 24–31. [Google Scholar] [CrossRef]
- Sqalli, H.; El Awadi, N.; Rancati, C. Biobankonomics: The sustainability indicators of biobanks. Med. Sci. 2020, 36, 282–285. [Google Scholar] [CrossRef]
- Webster, J.D.; Simpson, E.R.; Michalowski, A.M.; Hoover, S.B.; Simpson, R.M. Quantifying Histological Features of Cancer Biospecimens for Biobanking Quality Assurance Using Automated Morphometric Pattern Recognition Image Analysis Algorithms. J. Biomol. Tech. 2011, 22, 108–118. [Google Scholar] [PubMed]
All Samples (n = 2150) | |
---|---|
FFPE blocks | |
Median per cases [IQR] | 3 [2–3] |
At diagnosis | 741 |
Total | 917 |
Frozen tissue samples | |
Median per cases [IQR] | 4 [2–5] |
At diagnosis | 810 |
Total | 1010 |
Plasma samples | |
Median per cases [IQR] | 2 [2–4] |
At diagnosis | 104 |
Total | 156 |
Serum samples | |
Median per cases [IQR] | 2 [2–2] |
At diagnosis | 18 |
Total | 30 |
Cell pellet | |
Median per cases [IQR] | 2 [2–2] |
At diagnosis | 8 |
Total | 14 |
PBMC samples | |
Median per cases [IQR] | 2 [2–2] |
At diagnosis | 8 |
Total | 12 |
Total blood samples | |
Median per cases [IQR] | 1 [1–2] |
At diagnosis | 5 |
Total | 10 |
All Cases (n = 363) | |
---|---|
Consent | |
Unknown | 70 (19) |
Yes | 293 (81) |
Send by e-mail or postal mail, waiting a reply | 54 |
Cases included at diagnosis | 290 (80) |
Cases included at 1st relapse | 69 (19) |
Cases included at multiple relapse | 4 (1) |
FFPE Blocks per case, median [IQR] | 3 [2–3] |
Cases with ≥3 FFPE blocks | 177 (49) |
% of tumor cells, median [range] (n = 240) | 70 [1–100] |
Cold ischemia, median [IQR], minute (n = 228) | 20 [15–25] |
≤15 | 102 (45) |
>15 and ≤30 | 87 (38) |
>30 and ≤45 | 33 (14) |
>45 | 6 (3) |
Matched frozen tissue | 256 (71) |
Matched plasma | 49 (14) |
Matched serum | 16 (4) |
Matched PBMC | 6 (2) |
Matched total blood sample | 7 (2) |
Matched cell pellet | 7 (2) |
LYMPHOPATH network rereading | 120 (33) |
Tumor location | |
Mediastinum | 131 (36) |
Lymph node | 84 (23) |
Waldeyer’s ring | 49 (14) |
Broncho-pulmonary | 48 (13) |
Orbit/eye | 20 (6) |
Soft tissue and bone | 12 (3) |
Salivary gland | 10 (3) |
Thyroid | 5 (1) |
Skin | 3 (0.8) |
Spleen | 1 (0.3) |
Diagnosis | |
B-cell lymphoid proliferations and lymphomas | 244 (67) |
Precursor B-cell neoplasm | 1 (0.3) |
B-lymphoblastic leukemia/lymphoma, NOS | 1 (0.3) |
Mature B-cell neoplasms | 243 (67) |
Diffuse large B-cell lymphoma, NOS | 63 (17) |
Extranodal marginal zone lymphoma of MALT | 39 (11) |
Indolent B-cell lymphoma, not classified | 30 (8) |
Primary mediastinal B-cell lymphoma | 23 (6) |
Follicular lymphoma | 23 (6) |
Extraosseous plasmacytoma | 14 (4) |
Chronic lymphocytic leukemia/small lymphocytic lymphoma | 14 (4) |
Mantle cell lymphoma | 11 (3) |
Nodular lymphocyte predominant B-cell lymphoma | 7 (2) |
Large B-cell lymphoma, not classified | 4 (1) |
Nodal marginal zone lymphoma | 4 (1) |
Mediastinal Grey Zone Lymphoma | 3 (0.8) |
Plasmablastic lymphoma | 2 (0.6) |
Mature B-cell neoplasm, not classified | 2 (0.6) |
Lymphoplasmacytic lymphoma | 1 (0.3) |
Lymphomatoid granulomatosis | 1 (0.3) |
Burkitt Lymphoma | 1 (0.3) |
Diffuse large B-cell lymphoma associated with chronic inflammation | 1 (0.3) |
Classic Hodgkin lymphoma | 93 (26) |
Nodular sclerosis | 54 (15) |
Not classified | 31 (9) |
Mixed cellularity | 4 (1) |
Lymphocytes rich | 3 (0.8) |
Lymphocytes depleted | 1 (0.3) |
T-cell and NK-cell lymphoid proliferations and lymphomas | 20 (6) |
Precursor T-cell neoplasms | |
T-lymphoblastic leukemia/lymphoma, NOS | 6 (2) |
Mature T-cell and NK-cell neoplasms | 14 (4) |
Peripheral T-cell lymphoma, NOS | 4 (1) |
Extranodal NK/T-cell lymphoma, nasal-type | 4 (1) |
ALK-negative anaplastic large cell lymphoma | 4 (1) |
Nodal T-follicular helper (TFH) cell lymphoma, NOS | 2 (0.6) |
Lymphoid neoplasms, not classified | 5 (1) |
All Patient (n = 351) | |
---|---|
Patient with full dataset | 91 (25) |
Follow-up, median [IQR], m | 33 [12–87] |
Age at diagnosis, median [IQR], y | 58 [43–71] |
>60 | 166 (47) |
LDH count at diagnosis (U/i), median [IQR] | 446 [352–581] |
Elevated LDH at diagnosis | 55 (43) |
Status at last follow-up | |
Alive | 247 (70) |
Dead | 104 (30) |
Sex | |
Female | 152 (43) |
Male | 199 (57) |
Stage at diagnosis | |
I | 13 (17) |
II | 21 (27) |
III | 23 (30) |
IV | 20 (26) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bontoux, C.; Marcovich, A.; Goffinet, S.; Pesce, F.; Tanga, V.; Bohly, D.; Salah, M.; Washetine, K.; Messaoudi, Z.; Felix, J.-M.; et al. The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d’Azur, Nice, France). J. Pers. Med. 2023, 13, 1076. https://doi.org/10.3390/jpm13071076
Bontoux C, Marcovich A, Goffinet S, Pesce F, Tanga V, Bohly D, Salah M, Washetine K, Messaoudi Z, Felix J-M, et al. The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d’Azur, Nice, France). Journal of Personalized Medicine. 2023; 13(7):1076. https://doi.org/10.3390/jpm13071076
Chicago/Turabian StyleBontoux, Christophe, Aubiège Marcovich, Samantha Goffinet, Florian Pesce, Virginie Tanga, Doriane Bohly, Myriam Salah, Kevin Washetine, Zeineb Messaoudi, Jean-Marc Felix, and et al. 2023. "The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d’Azur, Nice, France)" Journal of Personalized Medicine 13, no. 7: 1076. https://doi.org/10.3390/jpm13071076